Compositions for probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides , Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli , anaerobic cocci, Ruminococcus, E. Coli, Gemmiger, Desulfamonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. A pharmaceutical composition comprising viable non-pathogenic Clostridia spores, a viable non-pathogenic Bacteroides , and a viable non-pathogenic Escherichia coli.
2. A food, a drink or a food supplement comprising a pharmaceutical composition of claim 1 .
3. The pharmaceutical composition of claim 1 , formulated for use in a human, an animal or a domesticated animal.
4. The pharmaceutical composition of claim 1 , comprising between about 10 3 to about 10 13 Clostridia spores.
5. The pharmaceutical composition of claim 1 , further comprising one or more viable non-pathogenic microorganisms selected from the group consisting of a Bacteroides, a Collinsella , a Fusobacteria, a Propionibacteria, a Lactobacilli , an anaerobic cocci , a Ruminococcus , an Escherichia coli , a Gemmiger , a Desulfomonas , and a Peptostreptococcus species.
6. The pharmaceutical composition of claim 1 , further comprising an acid suppressant, an antacid, an H2 antagonist, a proton pump inhibitor or a combination thereof.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated:
(a) as a lyophilised, pulverized or powdered formulation,
(b) as a suspension where microflora are suspended,
(c) as a liquid culture, or is lyophilised, pulverized or powdered, or
(d) as a pharmaceutical composition dissolved in saline.
8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated:
(a) as an enteric coated capsule, an enteric coated microcapsule, a powder suitable for reconstitution, a naso-duodenal infusion, or for delivery in the form of an enema or a colonoscopic infusion; or
(b) as a pharmaceutical composition added to: a food, a food additive, a dairy-based product, a soy-based product or a derivative thereof, a jelly or a yogurt.
9. The pharmaceutical composition of claim 1 , wherein the viable non-pathogenic Bacteroides, or the viable non-pathogenic Escherichia coli , is formulated as or formulated from:
(i) a disease-screened fresh homologous feces,
(ii) a freeze-dried disease-screened homologous feces,
(iii) a reconstituted feces, reconstituted using viable non-pathogenic or attenuated microorganisms,
(iv) a reconstituted feces, reconstituted using viable non-pathogenic or attenuated microorganisms derived from a disease-screened fresh homologous feces,
(v) a reconstituted feces, reconstituted using cultured viable non-pathogenic or attenuated microorganisms,
(vi) a reconstituted feces, reconstituted using cultured viable non-pathogenic or attenuated microorganisms derived from a disease-screened fresh homologous feces,
(vii) a synthetic fecal composition, wherein the synthetic fecal composition comprises a liquid culture preparation, or is derived from a liquid culture;
(viii) a synthetic fecal composition comprising a preparation of viable flora;
(ix) a synthetic fecal composition comprising a preparation of viable flora in proportional content that resembles a normal healthy human fecal flora, which does not include antibiotic resistant populations; or
(x) any combination thereof.
10. The pharmaceutical composition of claim 9 , wherein the synthetic fecal composition further comprises;
(a) an anaerobic cocci;
(b) a fungi or a Monilia;
(c) a bacteria of a species: Bacteroides, Collinsella , Fusobacteria, Propionibacteria, Lactobacilli, Ruminococcus, Escherichia coli, Gemmiger, Clostridium, Desulfomonas, Peptostreptococcus, Bifidobacterium ; or
(d) any combination of (a) to (c).
11. A pharmaceutical composition comprising non-pathogenic Clostridia spores and non-pathogenic Collinsella spores.
12. The pharmaceutical composition of claim 11 , consisting essentially of non-pathogenic Clostridia spores and non-pathogenic Collinsella spores.
13. The pharmaceutical composition of claim 12 , consisting essentially of non-pathogenic Clostridia spores and non-pathogenic Collinselia aerofaciens spores.
14. The pharmaceutical composition of claim 11 , further comprising non-pathogenic C. bifermentans, C. butyricum , and C. innocuum spores.
15. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is formulated as a lyophilised, pulverized or powdered formulation.
16. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is formulated as an enteric coated capsule, an enteric coated microcapsule, a powder suitable for reconstitution, a naso-duodenal infusion, or for delivery in the form of an enema or a colonoscopic infusion.
17. The pharmaceutical composition of claim 11 , wherein the pharmaceutical composition is formulated as a pharmaceutical composition added to: a food, a food additive, a dairy-based product, a soy-based product or a derivative thereof, a jelly or a yogurt.
18. The pharmaceutical composition of claim 11 , comprising between about 10 3 to about 10 13 Clostridia spores.
19. The pharmaceutical composition of claim 11 , further comprising at least one strain of a viable non-pathogenic Bacteroides.
20. The pharmaceutical composition of claim 19 , wherein the Bacteroides is selected from the group consisting of a Bacteroides caccae , a Pseudoflavonifractor capillosus , a Bacteroides coagulans , a Parabacteroides distasonis , a Bacteroides eggerthii , a Bacteroides orsythus , a Bacteroides fragilis , a Bacteroides gracilis , a Bacteroides levii, Bacteroides macacae , a Bacteroides merdae , a Bacteroides ovatus , a Bacteroides pneumosintes , a Bacteroides putredinis , a Bacteroides pyogenes , a Odoribacter splanchnicus , a Bacteroides stercoris , a Bacteroides tectum , a Bacteroides thetaiotaomicron, a Bacteroides uniformis , a Bacteroides ureolyticus , and a Bacteroides vulgatus.
21. The pharmaceutical composition of claim 11 , further comprising one or more viable non-pathogenic microorganisms selected from the group consisting of a Collisella , a Fusobacteria, a Propionibacteria, a Lactobacilli , an anaerobic cocci, a Ruminococcus , an Escherichia coli , a Gemmiger , a Desulfomonas , and a Peptostreptococcus species.